A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 May 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 27 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 08 Mar 2016 Results (pooled analysis of this and five other studies (n = 300) assessing olaparib monotherapy in patients with advanced relapsed BRCA1/2 ovarian cancer) published in the Annals of Oncology.
- 04 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.